Personalis, Inc. (NASDAQ:PSNL) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET

Company Participants

Caroline Corner – Investor Relations

Chris Hall – Chief Executive Officer and President

Aaron Tachibana – Chief Financial Officer and Chief Operating Officer

Rich Chen – Chief Medical Officer and Executive Vice President-R&D

Conference Call Participants

Mike Matson – Needham & Co.

Sean Lee – H.C. Wainwright

Operator

Greetings ladies and gentlemen. And welcome to Personalis’ First Quarter 2023 Earnings Conference Call. [Operator instructions] As a reminder this conference is being recorded.

I would now like to turn the conference over to Caroline Corner of Investor Relations.

Caroline Corner

Thank you, operator. Welcome to Personalis' first quarter 2023 earnings call.

Joining me on today's call are Chris Hall, Chief Executive Officer and President; and Aaron Tachibana, Chief Financial Officer and Chief Operating Officer; and Rich Chen, Chief Medical Officer and EVP R&D.

All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meaning of U.S. securities laws. For example, any statements regarding trends and expectations for our financial performance this year and longer term, cash runway, revenue expectations and timing, size and booking of orders, products, services, technology, clinical milestones, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations and our market opportunities, business outlook. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations.

We encourage you to review our most recent filings with the SEC, including the risk factors described in our recent Annual Report on Form 10-Q. Personalis undertakes no obligation to update these statements, except as required by applicable law.

Our press release for the first quarter 2023 results is available on our website, www.personalis.com, under the Investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review.

A recording of today’s call will be available on our website by 5 p.m. Pacific Time today.

Now, I’d like to turn the call over to Chris for his comments and first quarter business highlights.

Chris Hall

Thank you, Caroline. Good afternoon everyone. And thank you for joining us.

Since I was appointed CEO in March, I have only become more convinced that Personalis is uniquely positioned for its technology to power the two most important developments occurring in oncology. One, is creating personalized diagnostic assays to monitor patients with cancer; and the second is delivering personalized therapies to patients. Both of these developments in the management of patients require discriminating technology that is able to illuminate the uniqueness of each patient's tumor and provide actionable information that can change the arc of the disease.